Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologics and Blistering in Contact Dermatitis Model
NCT05535738Phase 3Active, not recruiting
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of dupilumab + topical corticosteroids, adalimumab, ustekinumab, guselkumab, canakinumab and 4 more in dermatitis and allergic contact dermatitis (ACD) (2 arms). Primary endpoint: Single-cell multiomics data (RNAseq, CITEseq, TCRseq) at 5 years. Started Nov 2022; status: active, not recruiting.
02
Drugs
03
Conditions
dermatitisallergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT05535738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535738.